Medimaa Diagnostics Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -32.52%
- Profit Growth -39.08%
- Ebitda 41.51%
- Net Worth 15.32%
- Total Assets 42.71%
About Medimaa Diagnostics
Medimaa Diagnostics Private Limited (MDPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 April 2019 (Five years and ten months 7 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Anubhav Verma and Ajay Saini serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U85100DL2019PTC348381
-
Company No.
348381
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
05 Apr 2019
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Medimaa Diagnostics?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anubhav Verma
|
Director | 04-Aug-2023 | Current |
|
Ajay Saini
|
Director | 29-Aug-2023 | Current |
Financial Performance of Medimaa Diagnostics.
Medimaa Diagnostics Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 32.52% decrease. The company also saw a substantial fall in profitability, with a 39.08% decrease in profit. The company's net worth Soared by an impressive increase of 15.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medimaa Diagnostics?
In 2023, Medimaa Diagnostics had a public holding of 50.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Preferential Enterprises LlpAnubhav Verma is a mutual person
-
Zupier Technologies Llp
Anubhav Verma is a mutual person
-
Posta Ventures Private Limited
Ajay Saini is a mutual person
-
Xoqovo Private Limited
Ajay Saini is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Medimaa Diagnostics?
Medimaa Diagnostics has a workforce of 2 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medimaa Diagnostics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medimaa Diagnostics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
